Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity.

Autores de IIS La Fe

• Antonio Conde Moreno

  Autor

Participantes ajenos a IIS La Fe

• López-Campos F
• Barrado Los Arcos M
• Gómez-Caamaño A
• García-Gómez R
• Hervás Morón A

Grupos

• Investigación Clínica y Traslacional en Cáncer

  

  Leader

  José Gómez Codina

Abstract

The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients-androgen deprivation therapy (ADT) alone-until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits-including significantly better overall survival (OS)-for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.

Keywords

• apalutamide; darolutamide; enzalutamide; nonmetastatic castration-resistant prostate cancer; overall survival; second generation anti-androgens